Glycine itself has minimal pharmacological effects at the concentrations used in these formulations
CONCLUSIONS GLP-1 RAs and multi-agonist therapies combining GLP-1 with GIP and/or GCG agonism embody transformative therapeutic approaches for MASLD/MASH, addressing multiple pathogenic pathways through complementary mechanisms of action
Statins are not contraindicated in patients with nonalcoholic fatty liver disease, and the risk of hepatotoxicity in these patients is not increased compared with the general population 2 (Table 6 13,3033 )
Sonne, D
Breakthrough medication: Lose up to 21% of your body weight in 72 weeks with once-weekly, clinically proven treatment
15 Who May Benefit Most From GLP-1s for Heart Health By addressing the root drivers of heart disease including inflammation, insulin resistance, and liver stress GLP-1s can be a powerful tool for anyone with significant cardiovascular risk, even if their weight is in the normal BMI range